Results 191 to 200 of about 1,964,480 (312)

ESR1 methylation and ESR1 mutations in circulating tumor cells (CTCs) and paired plasma‐cfDNA of advanced breast cancer patients: A feasibility proof‐of‐concept study

Molecular Oncology, EarlyView.
Circulating tumor cells (CTCs) and plasma cell‐free DNA (cfDNA) were analyzed to detect ESR1 mutations and methylation in patients with advanced breast cancer. CTC‐derived DNA showed higher sensitivity for mutation detection and revealed complementary genetic and epigenetic alterations, highlighting the added value of CTC analysis for understanding ...
Dimitra Stergiopoulou, Athina Markou, Eleonora Nicolo, Mara S Serafini, Qiang Zhang, Youbin Zhang, Lorenzo Gerratana, Andrew A. Davis, Huiping Liu, William J Gradishar, Carolina Reduzzi, Massimo Cristofanilli, Evi Lianidou   +12 more
wiley   +1 more source

Balloon-occluded hepatic arterial infusion for unresectable hepatocellular carcinoma: a phase II trial interim analysis. [PDF]

Front Oncol
Li F, Zhang J, An X, Liu J, Li B, Li H, Jun L, Wang N, Jiang G, Jiang Y, Zhang D, Gao F, Song L, Zhou J, Zheng W, Ji M, Wang F.   +16 more
europepmc   +1 more source

SusChem Switzerland, Phase II

CHIMIA, 2019
openaire   +4 more sources

Interpreting the effects of DNA polymerase variants at the structural level

Molecular Oncology, EarlyView.
Using MAVISp and molecular dynamics simulations, we analyzed over 60 000 missense variants in POLE and POLD1 from ClinVar, COSMIC, cBioPortal, and saturation mutagenesis. Identified mechanistic indicators, including stability, binding, and long‐range, enable structural interpretation, providing ACMG‐like evidence for possible reclassification of VUS ...
Matteo Arnaudi, Karolina Krzesińska, Ludovica Beltrame, Pablo Sánchez‐Izquierdo Besora, Matteo Tiberti, Mef Nilbert, Anna Rohlin, Elena Papaleo   +7 more
wiley   +1 more source

A Phase II Trial of Perioperative Camrelizumab Plus Neoadjuvant Chemotherapy in Resectable Stage IIB-IIIB Lung Squamous Cell Carcinoma. [PDF]

MedComm (2020)
Hu M, Liu S, Han Y, Wang F, Liu Y, Lu B, Li H, Gao Y, Wang Y, Yang W, Shi K, Xiao B, Wang Q, Du J, Lin H, Li X, Wang C, Zhang T.   +17 more
europepmc   +1 more source

SECARB Phase II and Phase III

Carbon Storage Project Review Meeting Virtual September 2020, 2020
openaire   +2 more sources

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Phase II randomised, placebo-controlled study to evaluate the efficacy and safety of an MK2 inhibitor in ankylosing spondylitis. [PDF]

RMD Open
Maksymowych WP, Yeshokumar A, Cerullo E, Lambert RGW, Śliwinska-Stańczyk P, Klimiuk P, Kepich R, Pachai C, Zhu M, Liu J, Landis J, Goti V, Greenberg S.   +12 more
europepmc   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Phase II trial of combination radiation, hormone, and immunotherapy in grade group 5 prostate cancer. [PDF]

J Immunother Cancer
Bryant JM, Sandoval M, Putney R, Trivedi P, Katende EN, Fink A, Naqvi SM, Kim Y, Yin V, Zhang J, Park JY, Serna A, Lam N, Pow-Sang J, Poch M, Li R, Manley BJ, Naghavi A, Torres-Roca J, Grass GD, Kim S, Latifi K, Hunt D, Johnstone P, Dhillon J, Rodriguez PC, Jain R, Fernandez DC, Yamoah K.   +28 more
europepmc   +1 more source